BR112016029024A2 - conjugados e composições de texafirina-pt(iv) para uso na superação da resistência à platina - Google Patents

conjugados e composições de texafirina-pt(iv) para uso na superação da resistência à platina

Info

Publication number
BR112016029024A2
BR112016029024A2 BR112016029024A BR112016029024A BR112016029024A2 BR 112016029024 A2 BR112016029024 A2 BR 112016029024A2 BR 112016029024 A BR112016029024 A BR 112016029024A BR 112016029024 A BR112016029024 A BR 112016029024A BR 112016029024 A2 BR112016029024 A2 BR 112016029024A2
Authority
BR
Brazil
Prior art keywords
compositions
texaphyrin
conjugates
platinum resistance
platinum
Prior art date
Application number
BR112016029024A
Other languages
English (en)
Other versions
BR112016029024A8 (pt
Inventor
Thiabaud Gregory
Arambula Jonathan
L Sessler Jonathan
H Siddik Zahid
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of BR112016029024A2 publication Critical patent/BR112016029024A2/pt
Publication of BR112016029024A8 publication Critical patent/BR112016029024A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage

Abstract

a presente divulgação se refere a conjugados ligados e composições de platina (iv) e de texafirina que compreendem uma texafirina e um agente de platina (iv). a presente divulgação fornece também composições farmacêuticas dos conjugados e composições. além disso, são fornecidos aqui métodos para o uso dos presentes compostos no tratamento de câncer, tal como um câncer resistente à platina.
BR112016029024A 2014-06-11 2015-06-11 composto, composição farmacêutica e uso BR112016029024A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462010841P 2014-06-11 2014-06-11
US201562135502P 2015-03-19 2015-03-19
PCT/US2015/035229 WO2015191797A1 (en) 2014-06-11 2015-06-11 Texaphyrin-pt(iv) conjugates and compositions for use in overcoming platinum resistance

Publications (2)

Publication Number Publication Date
BR112016029024A2 true BR112016029024A2 (pt) 2017-08-22
BR112016029024A8 BR112016029024A8 (pt) 2021-07-20

Family

ID=54834283

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016029024A BR112016029024A8 (pt) 2014-06-11 2015-06-11 composto, composição farmacêutica e uso

Country Status (13)

Country Link
US (3) US10406167B2 (pt)
EP (1) EP3154541A4 (pt)
JP (3) JP7304128B2 (pt)
KR (1) KR102412203B1 (pt)
CN (2) CN116178456A (pt)
AU (1) AU2015274589B2 (pt)
BR (1) BR112016029024A8 (pt)
CA (1) CA2950305C (pt)
IL (1) IL249453B (pt)
MX (2) MX2019015527A (pt)
SG (1) SG11201610306RA (pt)
WO (1) WO2015191797A1 (pt)
ZA (1) ZA201608194B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016029024A8 (pt) 2014-06-11 2021-07-20 Univ Texas composto, composição farmacêutica e uso
WO2018067551A1 (en) * 2016-10-03 2018-04-12 Board Of Regents, The University Of Texas System Texaphyrin and antitumor antibiotic conjugates
CN106543234B (zh) * 2016-10-14 2019-04-09 昆明理工大学 以饱和链为桥的手性双核铂配合物及其制备方法和应用
CN108732147B (zh) * 2018-04-23 2021-01-19 南京邮电大学 基于fret效应探测细胞凋亡过程的方法
JP2023547584A (ja) 2020-08-14 2023-11-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム マンガン化学療法、光音響イメージング、及び光温熱療法のためのテキサフィリン誘導体
CN114539320A (zh) * 2020-11-25 2022-05-27 北京大学 辐射激活的四价铂配合物及其用途
CN113292578A (zh) * 2021-05-21 2021-08-24 弗兰克·杰瑞·拉罗德 一种texaphyrin-叶酸螯合物及其制备方法与应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265823A (en) 1979-01-04 1981-05-05 Robert E. Kosinski Aurothiosteroids
US4980473A (en) 1985-01-18 1990-12-25 The Trustees Of Columbia University In The City Of New York Chemical probes for left-handed DNA and chiral metal complexes as Z-specific anti-tumor agents
JPS62207283A (ja) 1986-03-07 1987-09-11 Yoshinori Kitani 新規な白金錯体
US5072011A (en) 1988-02-02 1991-12-10 Johnson Matthey, Inc. Pt(IV) complexes
US5162509A (en) 1989-03-06 1992-11-10 Board Of Regents, The University Of Texas System Process for preparing expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5252720A (en) 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5599923A (en) 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5272142A (en) 1989-03-06 1993-12-21 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles and methods for treating tumors
US4935498A (en) 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5409915A (en) 1993-09-14 1995-04-25 The University Of Vermont And State Agricultural College Bis-platinum (IV) complexes as chemotherapeutic agents
US5624919A (en) 1993-09-14 1997-04-29 The University Of Vermont And State Agricultural College Trans platinum (IV) complexes
US5633354A (en) 1994-09-21 1997-05-27 Pharmacyclics, Inc. Phosphoramidite derivatives of texaphyrins
US5591422A (en) 1995-06-02 1997-01-07 Pharmacyclics, Inc. Texaphyrin complexes having improved functionalization
US5776925A (en) 1996-01-25 1998-07-07 Pharmacyclics, Inc. Methods for cancer chemosensitization
US5955586A (en) 1996-03-22 1999-09-21 Sessler; Jonathan L. Highly boronated derivatives of texaphyrins
WO1998024424A1 (en) 1996-12-03 1998-06-11 Rijksuniversiteit Utrecht Cisplatinum comprising pharmaceutical
AU4232199A (en) * 1998-06-05 1999-12-20 Board Of Regents, The University Of Texas System Texaphyrin conjugates and uses thereof
WO2001032211A2 (en) 1999-10-29 2001-05-10 Pharmacyclics, Inc. Conjugate compounds for treating atheroma and other diseases
US7112671B2 (en) 2000-08-30 2006-09-26 Pharmacyclics, Inc. Non-symmetric tripyrranes in the synthesis of novel macrocycles
FR2873037B1 (fr) 2004-07-13 2008-04-11 Univ Pasteur Methodes et compositions pour le traitement de cancers
CZ2004964A3 (cs) 2004-09-14 2006-03-15 Pliva-Lachema A. S. Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
CA2595236A1 (en) * 2005-01-19 2006-07-27 Pharmacyclics, Inc. A method for treating neurologic diseases
US8246967B2 (en) 2005-08-02 2012-08-21 Macdonnell Frederick M Compounds with modifying activity enhanced under hypoxic conditions
US20070072838A1 (en) 2005-09-26 2007-03-29 Pharmacyclics, Inc. High-purity texaphyrin metal complexes
TW200728315A (en) 2005-12-06 2007-08-01 Nippon Chemical Ind Phosphorus transition-metal complex, method of producing the same, and anticancer agent forming the same
US20120164230A1 (en) 2007-05-08 2012-06-28 Rodney Feazell Soluble Nanoparticles as Delivery Systems for Prodrugs
PL2173337T3 (pl) 2007-08-06 2014-11-28 Univ Ohio Fosfaplatyny i ich zastosowanie w leczeniu raków opornych na cisplatynę i karboplatynę
CN101125865B (zh) 2007-09-29 2010-09-08 广东药学院 手性钌配合物及其作为抗肿瘤药物的应用
US9265747B2 (en) 2008-08-26 2016-02-23 Massachusetts Institute Of Technology Platinum (IV) complexes for use in dual mode pharmaceutical therapy
MX2011009749A (es) 2009-03-20 2012-01-20 Univ Padova Complejos de oro (iii) con oligopeptidos funcionalizados con donadores de azufre y su uso como agentes antitumorales.
CN102725298B (zh) 2009-10-28 2015-07-01 香港大学 作为组蛋白脱乙酰酶抑制剂的羟基取代的金(iii)卟啉络合物
CN102058576B (zh) 2010-12-28 2012-07-25 中国科学院深圳先进技术研究院 顺铂前体药物及其制备方法、核壳纳米颗粒及其制备方法
WO2012138988A2 (en) 2011-04-07 2012-10-11 The Research Foundation Of The City University Of New York Organometallic anti-cancer complexes
KR20140074880A (ko) 2011-06-21 2014-06-18 메사추세츠 인스티튜트 오브 테크놀로지 암의 치료를 위한 조성물 및 방법
JP5179628B2 (ja) 2011-07-15 2013-04-10 ユニーテック株式会社 ４価白金錯体及びそれを含む医薬組成物
CN102408452B (zh) * 2011-12-13 2014-09-03 中山大学 四吡啶基卟啉桥联十字形四核铂配合物及其制备方法和抗肿瘤活性
US8729286B2 (en) 2012-05-10 2014-05-20 Massachusetts Institute Of Technology Platinum compounds as treatment for cancers, and related methods, kits, and compositions
US8828984B2 (en) 2012-11-19 2014-09-09 The University Of Hong Kong Gold(III) complexes containing N-heterocyclic carbene ligand, synthesis, and their applications in cancer treatment and thiol detection
WO2014160216A2 (en) 2013-03-13 2014-10-02 Massachusetts Institute Of Technology Dual targeting anticancer agents
WO2014165782A2 (en) 2013-04-05 2014-10-09 Massachusetts Institute Of Technology Compositions, methods, and kits comprising platinum compounds associated with a ligand comprising a targeting moiety
BR112016029024A8 (pt) 2014-06-11 2021-07-20 Univ Texas composto, composição farmacêutica e uso

Also Published As

Publication number Publication date
JP7304128B2 (ja) 2023-07-06
ZA201608194B (en) 2023-05-31
KR102412203B1 (ko) 2022-06-23
NZ726729A (en) 2023-08-25
IL249453B (en) 2021-01-31
US11389459B2 (en) 2022-07-19
US10406167B2 (en) 2019-09-10
US20200069698A1 (en) 2020-03-05
AU2015274589A1 (en) 2016-12-15
WO2015191797A1 (en) 2015-12-17
CN106572991A (zh) 2017-04-19
KR20170016933A (ko) 2017-02-14
US20170246182A1 (en) 2017-08-31
MX370673B (es) 2019-12-19
AU2015274589B2 (en) 2020-12-03
EP3154541A1 (en) 2017-04-19
SG11201610306RA (en) 2017-01-27
IL249453A0 (en) 2017-02-28
US20230113036A1 (en) 2023-04-13
CA2950305C (en) 2023-03-14
MX2016016419A (es) 2017-04-06
JP2021102616A (ja) 2021-07-15
MX2019015527A (es) 2022-06-17
JP2017519004A (ja) 2017-07-13
CA2950305A1 (en) 2015-12-17
EP3154541A4 (en) 2017-12-20
CN116178456A (zh) 2023-05-30
BR112016029024A8 (pt) 2021-07-20
JP2023078171A (ja) 2023-06-06

Similar Documents

Publication Publication Date Title
BR112016029024A2 (pt) conjugados e composições de texafirina-pt(iv) para uso na superação da resistência à platina
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
BR112018010720A8 (pt) agonistas do receptor de apelina e métodos de uso
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2015000829A1 (es) Inhibidores de histona desmetilasas
BR112014021531A2 (pt) composto, composição farmacêutica e usos dos mesmos
GB201209613D0 (en) New compounds
UY36075A (es) Derivados de tubulisina
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
DOP2015000108A (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
BR112016028835A2 (pt) derivados de auristatina e conjugados dos mesmos
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
BR112017003346B8 (pt) Derivados de pirazolopiridina, seus usos, e composição farmacêutica
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
CL2015001772A1 (es) Composición farmacéutica para el tratamiento de dolor cabeza, y método de preparación de la misma.
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
BR112017021190A2 (pt) composição farmacêutica e o uso da mesma
BR112016024421A2 (pt) composição farmacêutica, cápsula e uso da composição farmacêutica

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/40 (2006.01), A61K 47/00 (2006.01), A61P 3

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time